Unicycive Therapeutics (NASDAQ:UNCY) is a biotechnology firm that focuses on developing and commercializing innovative treatments for patients with kidney disease and renal conditions. Their portfolio includes Renazorb, a phosphate binder for managing hyperphosphatemia in patients with chronic kidney disease, and UNI-494, an investigational drug for the treatment of acute kidney injury, underscoring their commitment to addressing unmet medical needs in renal care. The company's objective is to improve patient outcomes and quality of life through the discovery, development, and commercialization of these novel therapeutic candidates. With a patient-centered approach, Unicycive Therapeutics strives to advance renal care and meet the complex challenges faced by individuals with kidney diseases.